The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance
Open accessAbstract
Multiple drug resistance (MDR), referring to the resistance of cancer cells to a broad spectrum of structurally and mechanistically unrelated drugs across membranes, severely impairs the response to chemotherapy and leads to chemotherapy failure. Overexpression of ATP binding cassette (ABC) transporters is a major contributing factor resulting in MDR, which can recognize and mediate the efflux of diverse drugs from cancer cells, thereby decreasing intracellular drug concentration. Therefore, modulators of ABC transporter could be used in combination with standard chemotherapeutic anticancer drugs to augment the therapeutic efficacy. This review summarizes the recent advances of important cancer-related ABC transporters, focusing on their physiological functions, structures, and the development of new compounds as ABC transporter inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 2×
“ABCC1 ABCC1 transporter is encoded by ABCC1 gene, with the weight of 190 kDa and contains 1580 amino acids (Cole et al., 1992).”
BackgroundSchinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · cited 2×
“Several chemo-sensitizers were tested in clinical trials, like cyclosporine A, tariquidar, however, they did not show satisfying therapeutic effects due to their high toxicity, drugdrug interactions and clinical trial design problems (Robey et al., 2018).”
BackgroundFlavonoids: biosynthesis, biological functions, and biotechnological applications
Falcone Ferreyra, M. L., Rius, S. P., & Casati, P. (2012) · Frontiers in Plant Science · doi:10.3389/fpls.2012.00222 · Cited by 1,831
Structure of a bacterial multidrug ABC transporter
Dawson, R. J. P., & Locher, K. P. (2006) · Nature · doi:10.1038/nature05155 · Cited by 1,279
The E. coli BtuCD Structure: A Framework for ABC Transporter Architecture and Mechanism
Locher, K. P., Lee, A. T., & Rees, D. C. (2002) · Science · doi:10.1126/science.1071142 · Cited by 1,023
Targeted expression of MYCN causes neuroblastoma in transgenic mice
Weiss, W. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.2985 · Cited by 870
Leier, I., Jedlitschky, G., Buchholz, U., Cole, S. P., Deeley, R. G., & Keppler, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46856-1 · Cited by 853
Allen, J. D., van Loevezijn, A., Rademaker-Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G., & Schinkel, A. H. (2002) · PubMed · Cited by 814
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Loe, D. W., Almquist, K. C., Deeley, R. G., & Cole, S. P. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9675 · Cited by 560
The P-glycoprotein multidrug transporter
Sharom, F. J. (2011) · Essays in Biochemistry · doi:10.1042/bse0500161 · Cited by 509
GENETIC ANALYSIS OF THE MULTIDRUG TRANSPORTER
Gottesman, M. M., Hrycyna, C. A., Schoenlein, P. V., Germann, U. A., & Pastan, I. (1995) · Annual Review of Genetics · doi:10.1146/annurev.ge.29.120195.003135 · Cited by 478
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
Alam, A., Kowal, J., Broude, E., Roninson, I., & Locher, K. P. (2019) · Science · doi:10.1126/science.aav7102 · Cited by 469
Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation
Kim, Y., & Chen, J. (2018) · Science · doi:10.1126/science.aar7389 · Cited by 456
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
Structure of the human multidrug transporter ABCG2
Taylor, N. M. I., Manolaridis, I., Jackson, S. M., Kowal, J., Stahlberg, H., & Locher, K. P. (2017) · Nature · doi:10.1038/nature22345 · Cited by 418
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Natarajan, K., Xie, Y., Baer, M. R., & Ross, D. D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.002 · Cited by 405
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
Pharmacological Strategies for Overcoming Multidrug Resistance
Nobili, S., Landini, I., Giglioni, B., & Mini, E. (2006) · Current Drug Targets · doi:10.2174/138945006777709593 · Cited by 393
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1
Johnson, Z. L., & Chen, J. (2017) · Cell · doi:10.1016/j.cell.2017.01.041 · Cited by 375
High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter
Özvegy-Laczka, C., Hegedűs, T., Várady, G., Ujhelly, O., Schuetz, J. D., Váradi, A., Kéri, G., Őrfi, L., Német, K., & Sarkadi, B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1485 · Cited by 340
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Moody, J. E., Millen, L., Binns, D., Hunt, J. F., & Thomas, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200228200 · Cited by 330
Liang, Z., Wu, H., Xia, J., Li, Y., Zhang, Y., Huang, K., Wagar, N., Yoon, Y., Cho, H. T., Scala, S., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.10.017 · Cited by 330
Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain
Bakos, É., Evers, R., Szakács, G., Tusnády, G. E., Welker, E., Szabó, K., de Haas, M., van Deemter, L., Borst, P., Váradi, A., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.48.32167 · Cited by 326
Interactions of the Human Multidrug Resistance Proteins MRP1 and MRP2 with Organic Anions
Bakos, É., Evers, R., Sinkó, E., Váradi, A., Borst, P., & Sarkadi, B. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26477-4 · Cited by 322
Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
Jackson, S. M., Manolaridis, I., Kowal, J., Zechner, M., Taylor, N. M. I., Bause, M., Bauer, S., Bartholomaeus, R., Bernhardt, G., Koenig, B., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0049-1 · Cited by 321
P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review
Abdallah, H. M., Al-Abd, A. M., El-Dine, R. S., & El-Halawany, A. M. (2015) · Journal of Advanced Research · doi:10.1016/j.jare.2014.11.008 · Cited by 319
Zhou, S.-F., Wang, L.-L., Di, Y., Xue, C., Duan, W., Li, C., & Li, Y. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785132870 · Cited by 318
Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future
Cole, S. P. C. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135959 · Cited by 309
Dulucq, S., Bouchet, S., Turcq, B., Lippert, E., Etienne, G., Reiffers, J., Molimard, M., Krajinovic, M., & Mahon, F.-X. (2008) · Blood · doi:10.1182/blood-2008-03-147744 · Cited by 236
Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states
Manolaridis, I., Jackson, S. M., Taylor, N. M. I., Kowal, J., Stahlberg, H., & Locher, K. P. (2018) · Nature · doi:10.1038/s41586-018-0680-3 · Cited by 228
Amiri-Kordestani, L., Basseville, A., Kurdziel, K., Fojo, A. T., & Bates, S. E. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.002 · Cited by 219
Dohse, M., Scharenberg, C., Shukla, S., Robey, R. W., Volkmann, T., Deeken, J. F., Brendel, C., Ambudkar, S. V., Neubauer, A., & Bates, S. E. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031302 · Cited by 216
ABCG2 transports anticancer drugs via a closed-to-open switch
Orlando, B. J., & Liao, M. (2020) · Nature Communications · doi:10.1038/s41467-020-16155-2 · Cited by 198 · cited 1×
“The function of cavity 1 is to accommodate potential substrates, especially the flat, polycylic and hydrophobic ones, while cavity 2 possesses lower affinity for these substrates because of its less pronounced hydrophobic interface (Orlando and Liao, 2020).”
BackgroundAhmed-Belkacem, A., Pozza, A., Muñoz-Martínez, F., Bates, S. E., Castanys, S., Gamarro, F., Di Pietro, A., & Pérez-Victoria, J. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1817 · Cited by 196
Effect of quercetin on hoechst 33342 transport by purified and reconstituted p-glycoprotein
Shapiro, A. B., & Ling, V. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00826-x · Cited by 194
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
Christie, E. L., Pattnaik, S., Beach, J., Copeland, A., Rashoo, N., Fereday, S., Hendley, J., Alsop, K., Brady, S. L., Lamb, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09312-9 · Cited by 193
Snapshots of the maltose transporter during ATP hydrolysis
Oldham, M. L., & Chen, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108858108 · Cited by 192
Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1
Alam, A., Küng, R., Kowal, J., McLeod, R. A., Tremp, N., Broude, E. V., Roninson, I. B., Stahlberg, H., & Locher, K. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717044115 · Cited by 187
Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects
Ahmed, S., Khan, H., Aschner, M., Mirzae, H., Küpeli Akkol, E., & Capasso, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165622 · Cited by 182
Chapuy, B., Koch, R., Radunski, U., Corsham, S., Cheong, N., Inagaki, N., Ban, N., Wenzel, D., Reinhardt, D., Zapf, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.103 · Cited by 162
Boumendjel, A., Di Pietro, A., Dumontet, C., & Barron, D. (2002) · Medicinal Research Reviews · doi:10.1002/med.10015 · Cited by 162
Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications
Toyoda, Y., Takada, T., & Suzuki, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00208 · Cited by 162
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
Jordanides, N. E., Jorgensen, H. G., Holyoake, T. L., & Mountford, J. C. (2006) · Blood · doi:10.1182/blood-2006-02-003145 · Cited by 158
Cryo-EM structure of the ABCG2 E211Q mutant bound to estrone 3-sulfate and 5D3-Fab
Manolaridis, I., Jackson, S. M., Taylor, N. M. I., Kowal, J., Stahlberg, H., & Locher, K. P. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6hco/pdb · Cited by 146
Piperine as a Potential Anti-cancer Agent: A Review on Preclinical Studies
Manayi, A., Nabavi, S. M., Setzer, W. N., & Jafari, S. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170523120656 · Cited by 143
A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity
Henrich, C. J., Bokesch, H. R., Dean, M. C., Bates, S. E., Robey, R. W., Goncharova, E. I., Wilson, J. A., & McMahon, J. B. (2006) · SLAS DISCOVERY · doi:10.1177/1087057105284576 · Cited by 142
The therapeutic potential of targeting ABC transporters to combat multi-drug resistance
Bugde, P., Biswas, R., Mérien, F., Lu, J., Liu, D., Chen, M., Zhou, S., & Li, Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1310841 · Cited by 142
The Inhibitor Ko143 Is Not Specific for ABCG2
Weidner, L. D., Zoghbi, S. S., Lu, S., Shukla, S., Ambudkar, S. V., Pike, V. W., Mulder, J., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225482 · Cited by 141
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer
Syed, S. B., Arya, H., Fu, I., Yeh, T., Periyasamy, L., Hsieh, H., & Coumar, M. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-08062-2 · Cited by 133
Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP
Gameiro, M., Silva, R. V. D. S., Rocha‐Pereira, C., Carmo, H., Carvalho, F. D., Bastos, M. D. L., & Remião, F. (2017) · Molecules · doi:10.3390/molecules22040600 · Cited by 131
ABC proteins in antigen translocation and viral inhibition
Parcej, D. N., & Tampé, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.410 · Cited by 126
Henderson, M. J., Haber, M., Porro, A., Munoz, M. A., Iraci, N., Xue, C., Murray, J. E., Flemming, C. L., Smith, J. L., Fletcher, J. I., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr256 · Cited by 126
In vitro effect of quercetin on human gastric carcinoma: Targeting cancer cells death and MDR
Borska, S., Chmielewska, M., Wysocka, T., Drąg‐Zalesińska, M., Zabel, M., & Dzięgiel, P. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.06.035 · Cited by 122
Sims, J. T., Ganguly, S. S., Bennett, H., Friend, J. W., Tepe, J., & Plattner, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055509 · Cited by 121
Bram, E. E., Stark, M., Raz, S., & Assaraf, Y. G. (2009) · Neoplasia · doi:10.1593/neo.91314 · Cited by 119
Eid, S. Y., El-Readi, M. Z., & Wink, M. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.08.010 · Cited by 116
Porro, A., Haber, M., Diolaiti, D., Iraci, N., Henderson, M. J., Gherardi, S., Valli, E., Munoz, M. A., Xue, C., Flemming, C. L., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.078584 · Cited by 114
Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1)
Bakos, É., Evers, R., Calenda, G., Tusnády, G., Szakács, G., Váradi, A., & Sarkadi, B. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.24.4451 · Cited by 114
X-ray structure of the Yersinia pestis heme transporter HmuUV
Woo, J., Zeltina, A., Goetz, B. A., & Locher, K. P. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2417 · Cited by 113
Inhibition of P-Glycoprotein-Mediated Paclitaxel Resistance by Reversibly Linked Quinine Homodimers
Pires, M. M., Emmert, D., Hrycyna, C. A., & Chmielewski, J. A. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050492 · Cited by 112
Quantification and Characterization of P-Glycoprotein−Substrate Interactions
Gatlik-Landwojtowicz, E., Äänismaa, P., & Seelig, A. (2006) · Biochemistry · doi:10.1021/bi051380+ · Cited by 111
Adamska, A., & Falasca, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i29.3222 · Cited by 108
Raaijmakers, M. H. G. P., de Grouw, E. P. L. M., Heuver, L. H. H., van der Reijden, B. A., Jansen, J. H., Scheper, R. J., Scheffer, G. L., de Witte, T. J. M., & Raymakers, R. A. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0212 · Cited by 106
A common mechanism for ATP hydrolysis in ABC transporter and helicase superfamilies
Geourjon, C., Orelle, C., Steinfels, E., Blanchet, C., Deléage, G., Pietro, A. D., & Jault, J. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01907-7 · Cited by 96
Liu, X., Tee, H.-W., & Go, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.006 · Cited by 95
MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp
Lu, C., Shan, Z., Li, C., & Yang, L. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.139 · Cited by 94
Orlando, U. D., Castillo, A. F., Medrano, M. A. R., Solano, A. R., Maloberti, P. M., & Podesta, E. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.005 · Cited by 92
Zander, S. A. L., Kersbergen, A. J., van der Burg, E., de Water, N., van Tellingen, O., Gunnarsdottir, S., Jaspers, J. E., Pajic, M., Nygren, A. O. H., Jonkers, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3367 · Cited by 89
Fu, P., Kong, F., Li, X., Wang, Y., & Zhu, W. (2014) · Organic Letters · doi:10.1021/ol501523d · Cited by 89
ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS
W. Robey, R., R. Massey, P., Amiri-Kordestani, L., & E. Bates, S. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794473957 · Cited by 85
Chen, Y., Huang, W., Wei, Y.-L., Hsu, S.-C., Yuan, P., Lin, H. Y., Wistuba, I. I., Lee, J. J., Yen, C.-J., Su, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021428 · Cited by 84
Kraege, S., Stefan, K., Juvale, K., Ross, T., Willmes, T., & Wiese, M. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.067 · Cited by 82
The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion
Khunweeraphong, N., Stockner, T., & Kuchler, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-11794-w · Cited by 82
Gonçalves, B. M. F., Cardoso, D., & Ferreira, M. U. (2020) · Molecules · doi:10.3390/molecules25153364 · Cited by 82
Hegedüs, C., Truta-Feles, K., Antalffy, G., Várady, G., Német, K., Özvegy‐Laczka, C., Kéri, G., Őrfi, L., Szakács, G., Settleman, J. E., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.04.010 · Cited by 81
Huang, X., Xiao, X., Zhang, Y., Talele, T. T., Salim, A. A., Chen, Z., & Capon, R. J. (2014) · Marine Drugs · doi:10.3390/md12073818 · Cited by 79
Human ABC transporter isoform B6 (ABCB6) localizes primarily in the Golgi apparatus
Tsuchida, M., Emi, Y., Kida, Y., & Sakaguchi, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.027 · Cited by 75
SUN, L., Chen, W., Qu, L., Wu, J., & Jin, S. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1742 · Cited by 75
P‐glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer’s Disease
Sita, G., Hrelia, P., Tarozzi, A., & Morroni, F. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7905486 · Cited by 75
miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma
Li, Y., Liu, Y., Ren, J. F., Deng, S., Yi, G., Guo, M., Shu, S., Zhao, L., Peng, Y.-P., & Qi, S. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2835-3 · Cited by 74
Takada, T., Yamamoto, T., Matsuo, H., Tan, J. K., Ooyama, K., Sakiyama, M., Miyata, H., Yamanashi, Y., Toyoda, Y., Higashino, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29208-w · Cited by 70
Stefan, K., Stefan, S. M., & Wiese, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00788 · Cited by 67
Ishikawa, T., Aw, W., & Kaneko, K. (2013) · Pharmaceuticals · doi:10.3390/ph6111347 · Cited by 66
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
Ball, B. J., Zeidan, A. M., Gore, S. D., & Prébet, T. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1228927 · Cited by 65
Kashiwayama, Y., Seki, M., Yasui, A., Murasaki, Y., Morita, M., Yamashita, Y., Sakaguchi, M., Tanaka, Y., & Imanaka, T. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.031 · Cited by 63
Erlotinib antagonizes ABC transporters in acute myeloid leukemia
Lainey, É., Sébert, M., Thépot, S., Scoazec, M., Bouteloup, C., Leroy, C., de Botton, S., Galluzzi, L., Fenaux, P., & Kroemer, G. (2012) · Cell Cycle · doi:10.4161/cc.22382 · Cited by 63
Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Sipholane Triterpenoids
Jain, S. K., Laphookhieo, S., Shi, Z., Fu, L., Akiyama, S.-I., Chen, Z., Youssef, D. T. A., van Soest, R. W. M., & Sayed, K. A. E. (2007) · Journal of Natural Products · doi:10.1021/np0605889 · Cited by 63
Zhan, M., Zhao, X., Wang, H., Chen, W., Xu, S., Wang, W., Shen, H., Huang, S., & Wang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-4957-6 · Cited by 63
The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid
Khunweeraphong, N., Szöllősi, D., Stockner, T., & Kuchler, K. (2019) · Nature Communications · doi:10.1038/s41467-019-13302-2 · Cited by 63
Zhang, H., Patel, A. S., Ma, S., Li, X. J., Zhang, Y.-K., Yang, P., Kathawala, R. J., Wang, Y., Anreddy, N., Fu, L., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12889 · Cited by 62
Zhang, G.-N., Zhang, Y., Wang, Y., Gupta, P., Ashby, C. R., Alqahtani, S., Deng, T., Bates, S. E., Kaddoumi, A., Wurpel, J. N. D., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.040 · Cited by 61
Sultan, M., Vidovic, D., Paine, A. S., Huynh, T. T., Coyle, K. M., Thomas, M. L., Cruickshank, B. M., Dean, C. A., Clements, D. R., Kim, Y., et al. (2018) · Stem Cells · doi:10.1002/stem.2780 · Cited by 60
Shi, Z., Jain, S. K., Kim, I., Peng, X., Abraham, I., Youssef, D. T. A., Fu, L., Sayed, K. A. E., Ambudkar, S. V., & Chen, Z. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00554.x · Cited by 59
Wang, S., Liu, S., Zhao, B., Yang, F., Wang, Y.-T., Liang, Q., Sun, Y., Liu, Y., Song, Z., Cai, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4536 · Cited by 59
Lorendeau, D., Dury, L., Genoux‐Bastide, E., Lecerf-Schmidt, F., Simões‐Pires, C. A., Carrupt, P., Terreux, R., Magnard, S., Pietro, A. D., Boumendjel, A., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.05.017 · Cited by 57
Nabekura, T., Yamaki, T., & Kitagawa, S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.025 · Cited by 56
MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.
Tian, J., Xu, Y., Li, L., & Hao, Q. (2017) · PubMed Central · Cited by 56
Silbermann, K., Shah, C. P., Sahu, N. U., Juvale, K., Stefan, S. M., Kharkar, P. S., & Wiese, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.019 · Cited by 56
Chen, Z., Chen, Y., Xu, M., Chen, L., Zhang, X., To, K. K. W., Zhao, H., Wang, F., Xia, Z., Chen, X., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0939 · Cited by 55
Nilotinib in the Treatment of Chronic Myeloid Leukemia
Sacha, T., & Saglio, G. N. (2018) · Future Oncology · doi:10.2217/fon-2018-0468 · Cited by 54
Novel therapies for epilepsy in the pipeline
Mesraoua, B., Deleu, D., Kullmann, D. M., Shetty, A. K., Boon, P., Perucca, E., Mikati, M. A., & Asadi‐Pooya, A. A. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.042 · Cited by 54
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia
Lainey, É., Wolfromm, A., Marie, N., Enot, D. P., Scoazec, M., Bouteloup, C., Leroy, C., Micol, J.-B., de Botton, S., Galluzzi, L., et al. (2012) · Oncogene · doi:10.1038/onc.2012.469 · Cited by 52
Stefan, S. M., Stefan, K., & Wiese, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01644 · Cited by 52
Reustle, A., Fisel, P., Renner, O., Büttner, F., Winter, S., Rausch, S., Kruck, S., Nies, A. T., Hennenlotter, J., Scharpf, M. O., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31741 · Cited by 52
Wong, I. L. K., Wang, B.-C., Yuan, J., Duan, L.-X., Liu, Z., Liu, T., Li, X., Hu, X., Zhang, X., Jiang, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00085 · Cited by 50
Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo
Wei, Y., Xu, L., Liang, Y., Xu, X., & Zhao, X. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.19 · Cited by 50
Efflux mechanism and pathway of verapamil pumping by human P-glycoprotein.
Wang, L.-J., & Sun, Y. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108675 · Cited by 48
Ohtsuki, S., Kamoi, M., Watanabe, Y. S., et al. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.1144 · Cited by 47
Jiang, M., Zhang, R., Wang, Y., Jing, W., Liu, Y., Ma, Y., Sun, B., Wang, M., Chen, P., Liu, H., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00381 · Cited by 47
Sato, H., Siddig, S., Uzu, M., Suzuki, S., Nomura, Y., Kashiba, T., Gushimiyagi, K., Sekine, Y., Uehara, T., Arano, Y., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.021 · Cited by 45
Gaber, S. A. A., Müller, P., Zimmermann, W., Hüttenberger, D., Wittig, R., Kader, M. H. A., & Stepp, H. G. (2017) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2017.10.035 · Cited by 45
Gana, C. C., Hanssen, K. M., Yu, D. M. T., Flemming, C. L., Wheatley, M. S., Conseil, G., Cole, S. P. C., Norris, M. D., Haber, M., & Fletcher, J. I. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.07.009 · Cited by 45
Yin, H., Dong, J., Cai, Y., Shi, X., Wang, H., Liu, G., Tang, Y., Liu, J., & Ma, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.053 · Cited by 44
Self-citationHuang, Y., Dai, Y., Wen, C., He, S., Shi, J., Zhao, D., Wu, L., & Zhou, H. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.027 · Cited by 44
Sandeep, M. S., Vemulapalli, S., Puneeth, Y., Pingili, R. B., & Babu, K. N. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.819885 · Cited by 43
MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells
Li, C., Zou, J., Zheng, G., & Chu, J.-K. (2016) · Medical Science Monitor · doi:10.12659/msm.898415 · Cited by 43
Ding, Y., Li, S., Ge, W., Liu, Z., Zhang, X., Wang, M., Chen, T., Chen, Y., & Zhang, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111706 · Cited by 43
Nasr, R., Lorendeau, D., Khonkarn, R., Dury, L., Pérès, B., Boumendjel, A., Cortay, J., Falson, P., Chaptal, V., & Baubichon-Cortay, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-64400-x · Cited by 43
Rocha, G. D. G., de Oliveira, R. C., Kaplan, M. A. C., & Gattass, C. R. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.054 · Cited by 42
ABCG2 functions as a general phytoestrogen sulfate transporter in vivo
van de Wetering, K., & Sapthu, S. (2012) · The FASEB Journal · doi:10.1096/fj.12-210039 · Cited by 40
Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization
Obreque-Balboa, J. E., Sun, Q., Bernhardt, G., König, B., & Buschauer, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.010 · Cited by 39
Self-citationZhou, Z.-Y., Wan, L.-L., Yang, Q., Han, Y., Li, D., Lu, J., & Guo, C. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.07.710 · Cited by 39
Basu, R., Baumgaertel, N., Wu, S., & Kopchick, J. J. (2017) · Hormones and Cancer · doi:10.1007/s12672-017-0292-7 · Cited by 39
Drozd, E., Krzysztoń-Russjan, J., Marczewska, J., Drozd, J., Bubko, I., Bielak, M., Lubelska, K., Wiktorska, K., Chilmończyk, Z., Anuszewska, E., et al. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.06.051 · Cited by 38
Sharma, A. R., Vatapalli, R. J., Abdelfatah, E., McMahon, K. W., Kerner, Z. J., Guzzetta, A. A., Singh, J., Zahnow, C. A., Baylin, S. B., Yerram, S. R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176139 · Cited by 38
Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma
Zhou, X., Ding, J., Li, H., Zuo, J., Ge, S., Jia, H., & Wu, J. H. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15090 · Cited by 38
Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication
Munagala, S., Sirasani, G., Kokkonda, P., Phadke, M. A., Krynetskaia, N. F., Lu, P., Sharom, F. J., Chaudhury, S., AbdulHameed, M. D. M., Tawa, G. J., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.12.022 · Cited by 36
Vahedi, S., Chufán, E. E., & Ambudkar, S. V. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.07.014 · Cited by 36
Bharate, J. B., Singh, S., Wani, A., Sharma, S., Joshi, P., Khan, I. A., Kumar, A., Vishwakarma, R. A., & Bharate, S. B. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00246j · Cited by 35
Flavonoid dimers are highly potent killers of multidrug resistant cancer cells overexpressing MRP1
Dury, L., Nasr, R., Lorendeau, D., Comsa, E., Wong, I. L. K., Zhu, X., Chan, K., Chan, T. H., Chow, L. M. C., Falson, P., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.013 · Cited by 35
Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)
Antoni, F., Bause, M., Scholler, M., Bauer, S., Stark, S., Jackson, S. M., Manolaridis, I., Locher, K. P., König, B., Buschauer, A., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112133 · Cited by 35
Ambjørner, S. E. B., Wiese, M., Köhler, S. C., Svindt, J., Lund, X. L., Gajhede, M., Saaby, L., Brodin, B., Rump, S., Weigt, H., et al. (2020) · Cells · doi:10.3390/cells9030613 · Cited by 34
miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1
Li, Y., Zhao, L., Li, N., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5464 · Cited by 33
MDR1 Gene Polymorphisms and Imatinib Response in Chronic Myeloid Leukemia: A Meta-Analysis
Zu, B., Li, Y., Wang, X., He, D., Huang, Z., & Feng, W. (2014) · Pharmacogenomics · doi:10.2217/pgs.13.222 · Cited by 32
Cihalova, D., Čečková, M., Kučera, R., Klimeš, J., & Štaud, F. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.099 · Cited by 31
Li, Y., Zhai, Z., Li, H., Wang, X., Huang, Y., & Su, X. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.03.032 · Cited by 31
Traxl, A., Mairinger, S., Filip, T., Sauberer, M., Stanek, J., Poschner, S., Jäger, W. R., Zoufal, V., Novarino, G., Tournier, N., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01217 · Cited by 30
Zhang, Y., Guo, L., Huang, J., Sun, Y., He, F., Zloh, M., & Wang, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081966 · Cited by 30
Hai-ya, H., Niu, J., & Lü, Y. (2011) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.4551 · Cited by 29
Triterpenoids from Momordica balsamina: Reversal of ABCB1-mediated multidrug resistance
Ramalhete, C., Mulhovo, S., Molnar, J. A., & Ferreira, M. U. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.08.022 · Cited by 29
Gergely, J. E., Dorsey, A. E., Dimri, G. P., & Dimri, M. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22804 · Cited by 29
Conseil, G., Arama-Chayoth, M., Tsfadia, Y., & Cole, S. P. C. (2019) · The FASEB Journal · doi:10.1096/fj.201900140r · Cited by 29
The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
Porcelli, L., Giovannetti, E., Assaraf, Y. G., Jansen, G., Scheffer, G. L., Kathmann, I., Azzariti, A., Paradiso, A., & Peters, G. J. (2014) · Current Drug Targets · doi:10.2174/1389450116666141205145620 · Cited by 27
Csandl, M., Conseil, G., & Cole, S. P. C. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.069468 · Cited by 27
Teodori, E., Dei, S., Bartolucci, G., Perrone, M. G., Manetti, D., Romanelli, M. N., Contino, M., & Colabufo, N. A. (2017) · ChemMedChem · doi:10.1002/cmdc.201700239 · Cited by 26
Bram, E. E., Adar, Y., Mesika, N., Sabisz, M., Składanowski, A., & Assaraf, Y. G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054791 · Cited by 23
Zhang, W., Clair, D. K. S., Butterfield, D. A., & Vore, M. E. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw021 · Cited by 23
GSK1904529A, a Potent IGF‐IR Inhibitor, Reverses MRP1‐Mediated Multidrug Resistance
Gupta, P., Xie, M., Narayanan, S., Wang, Y., Wang, X., Yuan, T., Wang, Z., Yang, D., & Chen, Z. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25975 · Cited by 23
Fallatah, O., & Georges, E. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.08.014 · Cited by 23
Si, X., Gao, Z., Xu, F., & Zheng, Y. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23148 · Cited by 23
Self-citationWang, F., Miao, M., Sun, B., Wang, Z., Tang, X., Chen, Y., Zhao, K., Liu, X., & Liu, L. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.54 · Cited by 22
Weigl, K. E., Conseil, G., Rothnie, A. J., Arama-Chayoth, M., Tsfadia, Y., & Cole, S. P. C. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112615 · Cited by 20
Emmanouilidi, A., Casari, I., Akkaya, B. G., Maffucci, T., Furic, L., Guffanti, F., Broggini, M., Chen, X., Maxuitenko, Y. Y., Keeton, A. B., et al. (2020) · Cancers · doi:10.3390/cancers12082022 · Cited by 20
Jason, D. F., Keeton, A. B., Bernard, D., Larry, A., Sodani, K. S., Zhe-Sheng, C., & Piazza, G. A. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.30.20150108 · Cited by 19
In vitro vascular toxicity of tariquidar, a potential tool for in vivo PET studies
Durante, M., Frosini, M., Fusi, F., Neri, A., Sticozzi, C., & Saponara, S. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.07.015 · Cited by 15
Braunová, A., Kaňa, M., Kudláčová, J., Kostka, L., Bouček, J., Betka, J., Šírová, M., & Etrych, T. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110579 · Cited by 14
Liening, S., Scriba, G. K. E., Rummler, S., Weinigel, C., Kleinschmidt, T. K., Haeggström, J. Z., Werz, O., & Garscha, U. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.07.011 · Cited by 12
Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells
Huang, L., Hu, C., Benedetto, M. D., Varin, R., Liu, J., Jin, J. J., Wang, L., Vannier, J., Janin, A., Lu, H., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2819 · Cited by 9
Zhang, L., Mao, Y., Gao, Z., Chen, X., Li, X., Liu, Y., & Xia, G. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00573-9 · Cited by 9
Gewin, L. S., Summers, M. E., Harral, J. W., Gaskill, C. F., Khodo, S. N., Neelisetty, S., Sullivan, T. M., Hopp, K., Reese, J., Klemm, D. J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00629.2018 · Cited by 7
Cited by
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
Metadata
- Authors
- Xiao, H., Zheng, Y., Ma, L., Tian, L., & Sun, Q.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-04-19
- Volume
- 12
- Pages
- 648407-648407
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3154854350
- Cited by
- 263
- References
- 167
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.